PHILADELPHIA — Subcutaneous guselkumab outperformed placebo and, as with IV administration, appears to have “profound induction effects” on both clinical remission and endoscopic response in Crohn’s disease, a presenter told Healio. “Back at DDW, we presented the results of the GALAXI 2 and 3 study comparing guselkumab to not only placebo but to ustekinumab,”
The latest news from the ACR Annual Meeting, including perspectives and interviews with leading researchers and clinicians, plus archives of past meetings.
BOSTON — Pregnant women with very severe interstitial lung disease had fewer term deliveries and more preterm births and miscarriages vs. women with a lower…
The first multicenter evaluation of pre-transplant immune-checkpoint-inhibitors in hepatocellular carcinoma to show promising intention-to-treat survival, safety and rejection rates. Immune-checkpoint-inhibitors, either alone or combined with…
Older men with COPD experienced improved lung function, functional fitness and quality of life after partaking in a tai chi plus yoga program for 12…
The latest news from the ACR Annual Meeting, including perspectives and interviews with leading researchers and clinicians, plus archives of past meetings.
Many patients with IBD report persisting symptoms, despite resolution of the inflammatory process. Although by definition, a diagnosis of IBS cannot be made, the prevalence…
Measles cases increased globally by 20% in 2023, and roughly 22 million children missed their first measles vaccine dose, according to the CDC and WHO’s…
PHILADELPHIA — Liver transplant recipients who lived in counties with limited access to healthy food were at higher risk for developing diabetes following transplantation, according…
Enhance your knowledge and expertise in Inflammatory Bowel Disease (IBD) and other gastroenterology topics through sessions, workshops, and presentations.
Despite a lack of “gold standard” evidence surrounding cannabis use for musculoskeletal pain, rheumatologists must not turn a blind eye to how such products are…
